- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 517698, 8 pages
Sanguinarine Inhibits Vascular Endothelial Growth Factor Release by Generation of Reactive Oxygen Species in MCF-7 Human Mammary Adenocarcinoma Cells
1Department of Clinical Pharmacology, Chinese PLA General Hospital, Beijing 100853, China
2Chinese PLA General Hospital, Beijing 100853, China
3College of Pharmacy, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
4College of Pharmacy, Bengbu Medical College, Bengbu 233030, China
Received 24 January 2013; Revised 29 March 2013; Accepted 12 April 2013
Academic Editor: Richard Tucker
Copyright © 2013 Xian-zhe Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- W. Y. Choi, C. Y. Jin, M. H. Han et al., “Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3,” Anticancer Research, vol. 29, no. 11, pp. 4457–4465, 2009.
- H. Park, E. Bergeron, H. Senta et al., “Sanguinarine induces apoptosis of human osteosarcoma cells through the extrinsic and intrinsic pathways,” Biochemical and Biophysical Research Communications, vol. 399, no. 3, pp. 446–451, 2010.
- M. Sun, W. Lou, J. Y. Chun et al., “Sanguinarine suppresses prostate tumor growth and inhibits survivin expression,” Genes and Cancer, vol. 1, no. 3, pp. 283–292, 2010.
- M. Sun, C. Liu, N. Nadiminty et al., “Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion,” Prostate, vol. 72, no. 1, pp. 82–89, 2012.
- H. Tsukamoto, S. Kondo, Y. Mukudai et al., “Evaluation of anticancer activities of benzo [c] phenanthridine alkaloid sanguinarine in oral squamous cell carcinoma cell line,” Anticancer Research, vol. 31, no. 9, pp. 2841–2846, 2011.
- J. S. Lee, W. K. Jung, M. H. Jeong, T. R. Yoon, and H. K. Kim, “Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway,” International Journal of Toxicology, vol. 31, no. 1, pp. 70–77, 2012.
- G. Volpi, F. Facchinetti, N. Moretto, M. Civelli, and R. Patacchini, “Cigarette smoke and α,β-unsaturated aldehydes elicit VEGF release through the p38 MAPK pathway in human airway smooth muscle cells and lung fibroblasts,” British Journal of Pharmacology, vol. 163, no. 3, pp. 649–661, 2011.
- X. L. . He, P. Zhang, X. Z. Dong, M. H. Yang, S. L. Chen, and M. G. Bi, “JR6, a new compound isolated from Justicia procumbens, induces apoptosis in human bladder cancer EJ cells through caspase-dependent pathway,” Journal of Ethnopharmacology, vol. 144, pp. 284–292, 2012.
- J. Ye, M. H. Li, X. Long, H. J. Wan, and Z. Fan, “Molecular characterization of breast cancer cell line MCF-7,” The Practical Journal of Cancer, vol. 27, no. 2, pp. 116–119, 2012.
- P. Meier, A. Finch, and G. Evan, “Apoptosis in development,” Nature, vol. 407, no. 6805, pp. 796–801, 2000.
- J. C. Reed, “Apoptosis-based therapies,” Nature Reviews Drug Discovery, vol. 1, no. 2, pp. 111–121, 2002.
- W. S. Wu, “The signaling mechanism of ROS in tumor progression,” Cancer and Metastasis Reviews, vol. 25, no. 4, pp. 695–705, 2006.
- A. Rapisarda and G. Melillo, “Role of the VEGF/VEGFR axis in cancer biology and therapy,” Advances in Cancer Research, vol. 114, pp. 237–267, 2012.
- M. Das and H. Wakelee, “Targeting VEGF in lung cancer,” Expert Opinion on Therapeutic Targets, vol. 16, no. 4, pp. 395–406, 2012.
- J. Waltenberger, “VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus,” Biochemical Society Transactions, vol. 37, no. 6, pp. 1167–1170, 2009.
- J. Du, R. Xu, Z. Hu, et al., “PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1α expression in MCF-7 breast cancer cells,” PLoS ONE, vol. 6, no. 9, Article ID e25213, 2011.
- E. Shubbar, J. Vegfors, M. Carlström, S. Petersson, and C. Enerbäck, “Psoriasin, (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation,” Breast Cancer Research and Treatment, vol. 134, no. 1, pp. 71–80, 2012.
- T. Maraldi, C. Prata, C. Caliceti et al., “VEGF-induced ROS generation from NAD(P)H oxidases protects human leukemic cells from apoptosis,” International Journal of Oncology, vol. 36, no. 6, pp. 1581–1589, 2010.
- M. W. Chao, I. P. Po, R. J. Laumbach, J. Koslosky, K. Cooper, and M. K. Gordon, “DEP induction of ROS in capillary-like endothelial tubes leads to VEGF-A expression,” Toxicology, vol. 297, no. 1–3, pp. 34–46, 2012.
- J. Chen, B. Liu, J. Yuan et al., “Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production,” Molecular Oncology, vol. 6, no. 1, pp. 62–72, 2012.
- L. Zhang, M. Deng, and S. Zhou, “Tetramethylpyrazine inhibits hypoxia-induced pulmonary vascular leakage in rats via the ROS-HIF-VEGF pathway,” Pharmacology, vol. 87, no. 5-6, pp. 265–273, 2011.
- E. Monaghan-Benson and K. Burridge, “The regulation of vascular endothelial growth factor-induced microvascular permeability requires Rac and reactive oxygen species,” The Journal of Biological Chemistry, vol. 284, no. 38, pp. 25602–25611, 2009.